News

Press Release Issued:
IASIC Opposes the Removal of Cannabis from Schedule 1

BURLINGTON, Vermont – June 25, 2024 – The International Academy on the Science and Impact of Cannabis (IASIC) released its official statement against the proposed rescheduling of Cannabis from Schedule I to Schedule III of the Controlled Substances Act:

As physicians and concerned citizens of the United States of America, the International Academy on the Science and Impact of Cannabis believes that re-scheduling will have immediate and irreparable harm to the public health and vehemently oppose the removal of cannabis from Schedule 1. Specific objections include (1) The Department of Health and Human Services (HHS) inappropriately changed the definition of currently acceptable medical use (CAMU); (2) Even under the new definition, cannabis still does not meet the requirements for CAMU; (3) Proper regulation of cannabis as a schedule 3 drug cannot be achieved while non-medical cannabis commerce is allowed.

“HHS and those who are pushing rescheduling of cannabis are unaware or ignoring the huge amount of science on the medical harms of cannabis. There is zero benefit and only problems to be had from rescheduling,” said Eric A. Voth, MD, FACP, President and Chairman of the Board, The International Academy on the Science and Impact of Cannabis.

An official request for a hearing with the DEA has been submitted by IASIC during the current open comment period, with its leadership urging the presentation of medical and scientific research from its physician-driven organization of international experts on cannabis.

IASIC has provided substantial education and background on the impending harm of the proposed rescheduling in its monthly speaker series on June 11th as well as on the High Truths on Drugs and Addiction podcast with episode #182: High Truths on Drugs and Addiction on Rescheduling of Marijuana with IASIC.

Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado

January 4, 2023 No Comments

The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado. This was a retrospective cohort study of pregnancy-related hospitalizations co-coded with cannabis diagnosis codes in the Colorado Hospital Association from January 1, 2011, through December 31, 2018 (recreational cannabis began

Read More »

Prenatal Cannabis Exposure Associated with Mental Disorders in Children that Persist into Early Adolescence

November 16, 2022 No Comments

Prenatal cannabis exposure following the middle of the first trimester—generally after five to six weeks of fetal development—is associated with attention, social, and behavioral problems that persist as the affected children progress into early adolescence (11 and 12 years of age), according to new research supported by the National Institute on Drug Abuse (NIDA), part

Read More »

Marijuana Use Increased in Pregnant Women with HIV

December 20, 2021 No Comments

In this cohort study including 2310 pregnant and postpartum individuals living with HIV from the Surveillance Monitoring for Antiretroviral Toxicities (SMARTT) study, use of marijuana increased from 2007 to 2019 and was more frequent in locations with medical marijuana legalization. The prevalence of alcohol and opioid use did not change over that time. To read

Read More »

Cannabis Use in Pregnancy May Lead to a More Anxious, Aggressive Child

December 14, 2021 No Comments

Children of women who use marijuana during or soon after pregnancy are twice as likely as other kids to become anxious, aggressive or hyperactive, according to a new study (https://www.pnas.org/content/118/47/e2106115118). The findings add weight to a growing body of evidence linking cannabis use during pregnancy to psychiatric problems in children. The study does not, however,

Read More »

Epidemiological overview of multidimensional chromosomal and genome toxicity of cannabis exposure in congenital anomalies and cancer development

July 8, 2021 No Comments

Abstract: Cannabis and cannabinoids are implicated in multiple genotoxic, epigenotoxic and chromosomal-toxic mechanisms and interact with several morphogenic pathways, likely underpinning previous reports of links between cannabis and congenital anomalies and heritable tumours. However the effects of cannabinoid genotoxicity have not been assessed on whole populations and formal consideration of effects as a broadly acting

Read More »

UCSD Study: Docs Should Screen For Cannabis Use Disorder in Pregnant Women

April 30, 2021 No Comments

Women diagnosed with cannabis use disorder had babies who were more likely to be born preterm, have a low birth weight and be small for their gestational age — all factors that can require greater or more intense medical care or presage later health issues. https://www.nbcsandiego.com/news/local/ucsd-study-docs-should-screen-for-cannabis-use-disorder-in-pregnant-women/2584996/

Read More »

Cannabis can alter male sperm DNA changes associated with autism

March 30, 2021 No Comments

Parental cannabis use has been associated with adverse neurodevelopmental outcomes in offspring, but how such phenotypes are transmitted is largely unknown. Using reduced representation bisulphite sequencing (RRBS), we recently demonstrated that cannabis use is associated with widespread DNA methylation changes in human and rat sperm. Discs-Large Associated Protein 2 (DLGAP2), involved in synapse organization, neuronal

Read More »

First Medical Textbook on Cannabis in Medicine

Listen to podcast High Truths on Drugs and Addiction on your favorite platform. ​Hightruth.com

Most Recent News

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Read More »

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Read More »

IASIC Speaker Series Presents: Case Report on Cannabis-Induced Acute Encephalopathy in Elderly After Taking CBD

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Read More »
Scroll to Top